Alexza surges after inhaled antipsychotic drug gets support

Share this article:
Alexza surges after inhaled antipsychotic drug gets support
Alexza surges after inhaled antipsychotic drug gets support

Stock prices for Alexza Pharmaceuticals Inc. recently surged by 25% to 78 cents. This came after the Food and Drug Administration's  Psychopharmacologic Drugs Advisory Committee conditionally backed the drugmaker's plan to sell an inhaled antipsychotic drug. Adusave is approved for people with schizophrenia and bipolar mania. However, the panel's 9-8 vote was contingent on the company using a risk mitigation plan proposed by the FDA.

Share this article:

More in Products

Nurse technology contest seeks applications

Nurses who want to share the ways technology has led to a better student or patient outcome are invited to enter a contest that touts two $10,000 cash awards.

Accessory for swimming approved for cochlear implants

Accessory for swimming approved for cochlear implants ...

The Food and Drug Administration has approved the Aqua+ accessory, a waterproof, behind-the-ear product for cochlear implant recipients. The accessory allows Cochlear™ Nucleus® 5 and Nucleus 6 Implant recipients2 to ...

Non-Invasive Open Ventilation System approved

Non-Invasive Open Ventilation System approved

Breathe Technologies, which makes the Non-Invasive Open Ventilation (NIOV) System, said the Food and Drug Administration has granted the fifth 510(k) clearance for the product.